- Fueled by best-in-class technology and deep expertise in genome engineering and AI, PerturbAI is uniquely positioned to redefine therapeutic discovery, making it more scalable, translatable and cost-efficient - - Dataset of 8 million brain-wide cells, generated and analyzed in collaboration with NVIDIA, Allen Institute for Brain Science and 10x Genomics, establishes the largest causal map of gene function in living tissue, showcasing the power of PerturbAI's scalable discovery engine - SAN FRANCISCO, March 17, 2026 /PRNewswire/ -- PerturbAI, an AI-native therapeutics company accelerating drug discovery through systems-level understanding of diseases, emerged from stealth today with the public release of the world's largest in vivo CRISPR atlas. The 8 million-cell, brain-wide dataset represents the largest known causal genomics resource generated directly in living tissue.
